Search

Your search keyword '"Fulcher, G."' showing total 227 results

Search Constraints

Start Over You searched for: Author "Fulcher, G." Remove constraint Author: "Fulcher, G." Search Limiters Full Text Remove constraint Search Limiters: Full Text
227 results on '"Fulcher, G."'

Search Results

4. Evidence for X(3872) in Pb-Pb Collisions and Studies of its Prompt Production at root s(NN)=5.02 TeV

5. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

6. Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

7. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

8. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

9. A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care.

10. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

12. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

13. P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

14. Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program

15. Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: A longitudinal study

16. Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: A longitudinal study.

17. SUN-128 A CO-DESIGNED INTEGRATED DIABETES AND KIDNEY DISEASE MODEL OF CARE IMPROVES DIABETES SELF-CARE AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE.

18. SUN-129 ACTIVATION LEVELS AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE ATTENDING A CO-DESIGNED INTEGRATED MODEL OF CARE: A LONGITUDINAL STUDY.

19. A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations.

20. SUN-128 A CO-DESIGNED INTEGRATED DIABETES AND KIDNEY DISEASE MODEL OF CARE IMPROVES DIABETES SELF-CARE AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE

21. SUN-129 ACTIVATION LEVELS AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE ATTENDING A CO-DESIGNED INTEGRATED MODEL OF CARE: A LONGITUDINAL STUDY

23. Updated risk factors should be used to predict development of diabetes

26. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

27. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

28. 1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program

32. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

33. Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease

34. The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study

35. The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study.

36. Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease.

37. SUN-266 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE ATTENDING A CO-DESIGNED INTEGRATED MODEL OF CARE: A LONGITUDINAL STUDY.

38. Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease.

39. Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results from the Randomized CANVAS Program Trials

40. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

41. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program

42. HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment.

45. Canagliflozin and heart failure in Type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

47. Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program

48. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program

49. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

50. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Catalog

Books, media, physical & digital resources